MyH3: A Potential Drug Target and Biomarker (G4621)

Target Name: MYH3

NCBI ID: G4621

MYH3

MyH3: A Potential Drug Target and Biomarker

MyH3 (SMHCE), a protein that belongs to the superfamily of cysteine-rich proteins (SRP), has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, which consists of a long extracellular domain, a short transmembrane region, and a large intracellular tail, has led to a high degree of interest in the study of its functions and potential therapeutic applications.

The protein encoded by the SMHCE gene is a 166 amino acid protein that is expressed in various tissues and cells of the body. It is highly conserved in its sequence, with a high degree of identity between different isoforms, which suggests that it plays an important role in various cellular processes. One of the most significant features of MyH3 is its ability to interact with various molecules, including transcription factors, signaling proteins, and other proteins that are involved in cellular signaling pathways.

MyH3 has been shown to play a critical role in several cellular processes, including cell signaling, DNA replication, and repair, cell adhesion, and neurotransmission. It is involved in the regulation of various signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. It has also been shown to interact with various proteins that are involved in these signaling pathways, including TGF-β1, PAK2, and Nrf2.

In addition to its role in cellular signaling, MyH3 has also been shown to play a critical role in the development and progression of various diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has also been shown to be involved in the development of cancer, including breast cancer and colorectal cancer.

The potential therapeutic applications of MyH3 are vast and varied. For example, it could be used as a drug target for diseases that are caused by the over-expression or deregulation of its gene, such as cancer, neurodegenerative diseases, and autoimmune disorders. It could also be used as a biomarker for the diagnosis and monitoring of these diseases. Additionally, its conserved sequence and high degree of identity across different isoforms make it a promising candidate for use as a drug or biomarker for diseases that affect a wide range of cellular processes, including those that are not currently treatable.

In conclusion, MyH3 is a protein that has significant potential as a drug target or biomarker for a wide range of diseases. Its unique structure and conserved sequence make it a promising candidate for use in a variety of cellular processes and diseases. Further research is needed to fully understand its functions and potential therapeutic applications.

Protein Name: Myosin Heavy Chain 3

Functions: Muscle contraction

The "MYH3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYH3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets